Spinal Muscular Atrophy (SMA) Treatment Market Size, Revenue, Growth, Trend & Forecast Analysis, 2020 - 2027, By Disease Type, By Treatment, By Route of Administration, By Country, & By Region

  • Report Id: HCDHR 2415
  • Published Date: August, 2020
  • No of Pages: 150
  • Format: Electronic (PDF)
  • Publisher: DataHorizzon Research
  • Category:

Spinal Muscular Atrophy (SMA) Treatment Market Report Overview

Spinal Muscular Atrophy (SMA) Treatment market garnered a revenue of USD 1.24 billion in the year 2019 globally and is anticipated to grow at a compound annual growth (CAGR) of 14.6% over the forecast period (2020-2027).The market has been observed to be growing at a steady growth rate over the last three years, however with the impact of COVID-19 pandemic globally, the business conditions are expected to change. The market size may reduce significantly or increase with a spike depending on how the value chain has been affected in the entire process.

Players that are operational in the market for a longer period of time are anticipated to absorb the sudden changes, losses and increased operational costs better than those who have recently entered the market. The report focuses on numerous factors that are anticipated to impact the market growth directly and indirectly. The report categorically analyses the growth patterns of different segments based on multiple derivation models.

Both the qualitative and quantitative aspects have been covered under the report. The Spinal Muscular Atrophy (SMA) Treatment market report includes market size, drivers, restraints, opportunities and trends that will help you understand the market dynamics in detail. Moreover, the report will include market estimates & forecasts in terms of revenue for the overall market along with the segments mentioned in the study. The report focuses on providing a holistic view of the entire market scenario from multiple unmatched detailed analysis mentioned in the report.

What to expect from the report?

  • Spinal Muscular Atrophy (SMA) Treatment Total Available Market (TAM) Size
  • Spinal Muscular Atrophy (SMA) Treatment Serviceable Available Market (SAM) Size
  • Business Implications of COVID-19 on the Overall Market
  • Market Share/ Revenue Share (%) of Top Market Players in Total Market Size (2019)
  • Market Size & Forecast (2016-2027) At Country & Regional Level, By Segments
  • Overview & Analysis of Key Players Operating in the Market

Key Highlights:

Parameters

Description

COVID-19

Impact of COVID-19 on overall business scenario

Spinal Muscular Atrophy (SMA) Treatment Market Revenue 2020

Global market revenue in 2020 will be derived taking into various micro & macro level factors; along with COVID-19 pandemic

Competitive Analysis

Company Market Share Analysis, 2019 (%)

Supply Chain Analysis

Analysis pertaining to several participants of supply chain such as raw material suppliers, distributors, & OEMs along with others will be highlighted in the study

Data Route of Administration

Primary & Secondary Research, Internal Data Base & Company Annual Reports

Regions Included

North America, Europe, Asia Pacific, Latin America, & Middle East & Africa

Countries Included

U.S., Canada, U.K., Germany, France, Mexico, Brazil, China, India, Japan, South Korea, UAE, South Africa

Table of Contents
Chapter 1. Research Methodology & Data Sources
1.1. Data Analysis Models
1.2. Research Scope & Assumptions
1.3. List of Primary & Secondary Data Sources
Chapter 2. Executive Summary
Chapter 3. Spinal Muscular Atrophy (SMA) Treatment Market: Industry Analysis
3.1. Market segmentation
3.2. Supply chain analysis
3.3. Porter’s 5 forces analysis
3.4. PEST analysis
3.5. Market Dynamics
3.5.1. Market driver analysis
3.5.2. Market restraint analysis
3.5.3. Market opportunity analysis
3.6. Company Market Share Analysis, 2019
Chapter 4. Spinal Muscular Atrophy (SMA) Treatment Market: Disease Type Insights
4.1. Global Disease Type Historic Market Data & Future Forecasts, 2016-2027
4.2. Type 1
4.2.1. Historic Market Data & Future Forecasts, 2016-2027
4.2.2. Historic Market Data & Future Forecasts by Region, 2016-2027
4.3. Type 2
4.3.1. Historic Market Data & Future Forecasts, 2016-2027
4.3.2. Historic Market Data & Future Forecasts by Region, 2016-2027
4.4. Type 3
4.4.1. Historic Market Data & Future Forecasts, 2016-2027
4.4.2. Historic Market Data & Future Forecasts by Region, 2016-2027
4.5. Type 4
4.5.1. Historic Market Data & Future Forecasts, 2016-2027
4.5.2. Historic Market Data & Future Forecasts by Region, 2016-2027
Chapter 5. Spinal Muscular Atrophy (SMA) Treatment Market: Treatment Insights
5.1. Global Treatment Historic Market Data & Future Forecasts, 2016-2027
5.2. Gene Therapy
5.2.1. Historic Market Data & Future Forecasts, 2016-2027
5.2.2. Historic Market Data & Future Forecasts by Region, 2016-2027
5.3. Drug
5.3.1. Historic Market Data & Future Forecasts, 2016-2027
5.3.2. Historic Market Data & Future Forecasts, By Region, 2016-2027
Chapter 6. Spinal Muscular Atrophy (SMA) Treatment Market: Route of Administration Insights
6.1. Global Route of Administration Historic Market Data & Future Forecasts, 2016-2027
6.2. Oral
6.2.1. Historic Market Data & Future Forecasts, 2016-2027
6.2.2. Historic Market Data & Future Forecasts by Region, 2016-2027
6.3. Intrathecal
6.3.1. Historic Market Data & Future Forecasts, 2016-2027
6.3.2. Historic Market Data & Future Forecasts by Region, 2016-2027
Chapter 7. Spinal Muscular Atrophy (SMA) Treatment Market: Regional Insights
7.1. Global Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Region 2016-2027
7.2. North America
7.2.1. Historic Market Data & Future Forecasts, 2016-2027
7.2.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.2.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.2.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.2.5. U.S.
7.2.5.1. Historic Market Data & Future Forecasts, 2016-2027
7.2.5.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.2.5.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.2.5.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.2.6. Canada
7.2.6.1. Historic Market Data & Future Forecasts, 2016-2027
7.2.6.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.2.6.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.2.6.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.3. Europe
7.3.1. Historic Market Data & Future Forecasts, 2016-2027
7.3.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.3.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.3.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.3.5. U.K.
7.3.5.1. Historic Market Data & Future Forecasts, 2016-2027
7.3.5.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.3.5.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.3.5.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.3.6. Germany
7.3.6.1. Historic Market Data & Future Forecasts, 2016-2027
7.3.6.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.3.6.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.3.6.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.3.7. France
7.3.7.1. Historic Market Data & Future Forecasts, 2016-2027
7.3.7.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.3.7.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.3.7.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.4. Asia Pacific
7.4.1. Historic Market Data & Future Forecasts, 2016-2027
7.4.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.4.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.4.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.4.4.1. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.4.5. China
7.4.5.1. Historic Market Data & Future Forecasts, 2016-2027
7.4.5.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.4.5.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.4.5.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.4.6. India
7.4.6.1. Historic Market Data & Future Forecasts, 2016-2027
7.4.6.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.4.6.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.4.6.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.4.7. Japan
7.4.7.1. Historic Market Data & Future Forecasts, 2016-2027
7.4.7.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.4.7.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.4.7.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.4.8. South Korea
7.4.8.1. Historic Market Data & Future Forecasts, 2016-2027
7.4.8.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.4.8.3.
7.4.8.4. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.4.8.5. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.5. Latin America
7.5.1. Historic Market Data & Future Forecasts, 2016-2027
7.5.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.5.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.5.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.5.5. Brazil
7.5.5.1. Historic Market Data & Future Forecasts, 2016-2027
7.5.5.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.5.5.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.5.5.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.5.6. Mexico
7.5.6.1. Historic Market Data & Future Forecasts, 2016-2027
7.5.6.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.5.6.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.5.6.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.6. Middle East & Africa
7.6.1. Historic Market Data & Future Forecasts, 2016-2027
7.6.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.6.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.6.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.6.5. UAE
7.6.5.1. Historic Market Data & Future Forecasts, 2016-2027
7.6.5.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.6.5.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.6.5.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027
7.6.6. South Africa
7.6.6.1. Historic Market Data & Future Forecasts, 2016-2027
7.6.6.2. Historic Market Data & Future Forecasts, By Disease Type, 2016-2027
7.6.6.3. Historic Market Data & Future Forecasts, By Treatment, 2016-2027
7.6.6.4. Historic Market Data & Future Forecasts, By Route of Administration, 2016-2027

Chapter 8. Company Profiles
8.1. Cytokinetics, Inc.
8.1.1. Company Description
8.1.2. Financial Highlights
8.1.3. Product Portfolio
8.1.4. Strategic Initiatives
8.2. Novartis AG
8.2.1. Company Description
8.2.2. Financial Highlights
8.2.3. Product Portfolio
8.2.4. Strategic Initiatives
8.3. Avexis, Inc.
8.3.1. Company Description
8.3.2. Financial Highlights
8.3.3. Product Portfolio
8.3.4. Strategic Initiatives
8.4. F. Hoffmann – La Roche Ltd
8.4.1. Company Description
8.4.2. Financial Highlights
8.4.3. Product Portfolio
8.4.4. Strategic Initiatives
8.5. Ionis Pharmaceuticals, Inc
8.5.1. Company Description
8.5.2. Financial Highlights
8.5.3. Product Portfolio
8.5.4. Strategic Initiatives
8.6. Biogen
8.6.1. Company Description
8.6.2. Financial Highlights
8.6.3. Product Portfolio
8.6.4. Strategic Initiatives

List of Tables
Table 1 Spinal Muscular Atrophy (SMA) Treatment Market Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 2 Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Region, 2016-2027 (USD Billion)
Table 3 Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 4 Type 1 Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 5 Type 2 Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 6 Type 3 Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 7 Type 4 Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 8 Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 9 Gene Therapy Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 10 Drug Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 11 Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 12 Oral Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 13 Intrathecal Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 14 North America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 15 North America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 16 North America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 17 North America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 18 U.S. Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 19 U.S. Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 20 U.S. Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 21 U.S. Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 22 Canada Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 23 Canada Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 24 Canada Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 25 Canada Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 26 Europe Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 27 Europe Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 28 Europe Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 29 Europe Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 30 U.K. Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 31 U.K. Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USBillion)
Table 32 U.K. Market Spinal Muscular Atrophy (SMA) Treatment Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 33 U.K. Market Spinal Muscular Atrophy (SMA) Treatment Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 34 Germany Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 35 Germany Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 36 Germany Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 37 Germany Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 38 France Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 39 France Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 40 France Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 41 France Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 42 Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 43 Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 44 Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 45 Asia Pacific Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 46 China Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 47 China Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 48 China Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 49 China Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 50 India Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 51 India Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 52 India Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 53 India Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 54 Japan Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 55 Japan Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 56 Japan Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 57 Japan Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 58 South Korea Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 59 South Korea Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 60 South Korea Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 61 South Korea Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 62 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 63 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 64 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 65 Latin America Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 66 Brazil Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 67 Brazil Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 68 Brazil Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 69 Brazil Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 70 Mexico Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 71 Mexico Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 72 Mexico Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 73 Mexico Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 74 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 75 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 76 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 77 Middle East & Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 78 UAE Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 79 UAE Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 80 UAE Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 81 UAE Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)
Table 82 South Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, 2016-2027 (USD Billion)
Table 83 South Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Disease Type, 2016-2027 (USD Billion)
Table 84 South Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Treatment, 2016-2027 (USD Billion)
Table 85 South Africa Spinal Muscular Atrophy (SMA) Treatment Market Data & Future Forecasts, By Route of Administration, 2016-2027 (USD Billion)


List of Figures
Fig.1 Data Analysis Model
Fig.2 Spinal Muscular Atrophy (SMA) Treatment Market, by 2016-2027 (USD Billion)
Fig.3 Spinal Muscular Atrophy (SMA) Treatment Market Segmentation
Fig.4 Supply chain analysis
Fig.5 Spinal Muscular Atrophy (SMA) Treatment Market Driver Anlaysis
Fig.6 Spinal Muscular Atrophy (SMA) Treatment Market Restraint Analysis
Fig.7 Spinal Muscular Atrophy (SMA) Treatment Market Opportunity Analysis
Fig.8 Porters 5 Forces Model
Fig.9 PEST Analysis- Spinal Muscular Atrophy (SMA) Treatment Market
Fig.10 Company Market Share Analysis, 2019

Spinal Muscular Atrophy (SMA) Treatment Market Segmentation:

Spinal Muscular Atrophy (SMA) Treatment Market, By Disease Type (2016-2017)

  • Type 1
  • Type 2
  • Type 3
  • Type 4

Spinal Muscular Atrophy (SMA) Treatment Market, By Treatment (2016-2027)

  • Gene Therapy
  • Drug

Spinal Muscular Atrophy (SMA) Treatment Market, By Route of Administration (2016-2027)

  • Oral
  • Intrathecal

Spinal Muscular Atrophy (SMA) Treatment Market, By Region (2016-2027)

  • North America
    • S.
    • Canada
  • Europe
    • K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • South Africa

Major Players Operating in the Spinal Muscular Atrophy (SMA) Treatment Market:

  • Cytokinetics, Inc.
  • Novartis AG
  • Avexis, Inc.
  • Hoffmann – La Roche Ltd
  • Ionis Pharmaceuticals, Inc.
  • Biogen

Choose License Type

Single user
$3,960
Multi User
$4,950
Enterprise User
$5,940
Clear

Each market study on Reports Globe will be revised based on COVID-19 impact analysis

How can we help you?

Our salient features

Best Solution

We will help you understand value propositions of various reports across numerous domains and suggest the best possible solution to suffice your research needs.

Customized Research

Our team of analysts and consultants provide assistance for customized research requirements

Max ROI

Guaranteed maximum assistance to help you get your reports at the optimum prices, thereby ensuring maximum returns on investment.

24/7 Support

24X7 availability to help you through the buying process as well as answer any of your doubts.

We've Received Your Request

We Thank You for filling out your requirements. Our sales team will get in touch with you shortly.